Fernanda M. Garcia‐Garcia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fernanda M. Garcia‐Garcia has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Dionicio Angel Galarza-Delgado
Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
2 shared publications - Jesus Alberto Cardenas-De la Garza
Rheumatology Department, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
2 shared publications - Andrea Lizbeth Guajardo-Aldaco
Internal Medicine Department Hospital Universitario ‘Dr. José Eleuterio González’ Universidad Autónoma de Nuevo León Monterrey México
1 shared publication - Andres Avalos-Bishop
Plataforma INVEST Medicina UANL-KER Unit Mayo Clinic (KER Unit Mexico), Universidad Autónoma de Nuevo León Facultad de Medicina, Monterrey, Mexico
1 shared publication - Arnav Agarwal
University of Alberta
1 shared publication - Cassandra Michele Skinner-Taylor
Rheumatology Service of University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by BMJ in BMJ Medicine
- Vol. 5 (1) , e002780
Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review
- 8 October 2026
- Published by BMJ in BMJ Medicine
- Vol. 5 (1) , e002780
Open AccessValues, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review
- 7 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (4) , 884-887
Alopecia Areata Associated With Bimekizumab Therapy
- 7 November 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (4) , 884-887
Alopecia Areata Associated With Bimekizumab Therapy
- 3 June 2025
- Published by Wiley in Musculoskeletal Care
- Vol. 23 (2) , e70136
Relationship Between Nail Psoriasis Severity Index and Cardiovascular Risk Assessed by 10 Cardiovascular Risk Calculators
Objective: To determine the relationship between Nail Psoriasis Severity Index (NAPSI) and cardiovascular risk (CVR) assessed by 10 CVR calculators. Methods: Cross‐sectional, observational, and comparative study of psoriatic arthritis (PsA) patients aged 30–75, classified according to established diagnostic criteria. The NAPSI was assessed, classifying patients into two groups: with (≥ 1) and without (< 1) nail involvement. The CVR was evaluated through: Framingham (FRS) lipids and body mass index (BMI), American College of Cardiology/American Heart Association‐ Atherosclerotic Cardiovascular Disease 2013 (ACC/AHA ASCVD 2013), Systematic Coronary Risk Evaluation (SCORE), SCORE 2, SCORE‐Older Persons (OP), QRISK3, Reynolds Risk Score (RRS), Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) atherosclerotic cardiovascular disease (ASCVD) and PREVENT Heart Failure (HF) calculator. Group distribution was assessed using the Kolmogorov–Smirnov test. Comparisons were conducted accordingly with Chi‐Squared, T‐Student, U‐Mann–Whitney, and Kruskal–Wallis tests. Correlations were performed using Spearman's rho. Statistical significance was set at p ≤ 0.05. Results: Seventy‐one patients with PsA were included, 31 with nail involvement and 40 without. CVR score was higher in PsA patients with nail involvement using SCORE (2.0 (1.0–3.7) versus 1.0 (0.0–2.0), p = 0.02). Regarding CVR, positive correlations were found between NAPSI and the following calculators: ACC/AHA ASCVD 2013 (Spearman's rho = 0.202, p = 0.045), FRS BMI (Spearman's rho = 0.229, p = 0.027), SCORE (Spearman's rho = 0.344, p = 0.002), PREVENT ASCVD (Spearman's rho = 0.198, p = 0.049), and PREVENT HF (Spearman's rho = 0.291, p = 0.007). Conclusions: A NAPSI ≥ 1 score is related to higher CVR assessed through SCORE and positively correlates with ACC/AHA, PREVENT TM ASCVD, and PREVENT HF.
- 3 June 2025
- Published by Wiley in Musculoskeletal Care
- Vol. 23 (2) , e70136
Relationship Between Nail Psoriasis Severity Index and Cardiovascular Risk Assessed by 10 Cardiovascular Risk Calculators
Objective: To determine the relationship between Nail Psoriasis Severity Index (NAPSI) and cardiovascular risk (CVR) assessed by 10 CVR calculators. Methods: Cross‐sectional, observational, and comparative study of psoriatic arthritis (PsA) patients aged 30–75, classified according to established diagnostic criteria. The NAPSI was assessed, classifying patients into two groups: with (≥ 1) and without (< 1) nail involvement. The CVR was evaluated through: Framingham (FRS) lipids and body mass index (BMI), American College of Cardiology/American Heart Association‐ Atherosclerotic Cardiovascular Disease 2013 (ACC/AHA ASCVD 2013), Systematic Coronary Risk Evaluation (SCORE), SCORE 2, SCORE‐Older Persons (OP), QRISK3, Reynolds Risk Score (RRS), Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) atherosclerotic cardiovascular disease (ASCVD) and PREVENT Heart Failure (HF) calculator. Group distribution was assessed using the Kolmogorov–Smirnov test. Comparisons were conducted accordingly with Chi‐Squared, T‐Student, U‐Mann–Whitney, and Kruskal–Wallis tests. Correlations were performed using Spearman's rho. Statistical significance was set at p ≤ 0.05. Results: Seventy‐one patients with PsA were included, 31 with nail involvement and 40 without. CVR score was higher in PsA patients with nail involvement using SCORE (2.0 (1.0–3.7) versus 1.0 (0.0–2.0), p = 0.02). Regarding CVR, positive correlations were found between NAPSI and the following calculators: ACC/AHA ASCVD 2013 (Spearman's rho = 0.202, p = 0.045), FRS BMI (Spearman's rho = 0.229, p = 0.027), SCORE (Spearman's rho = 0.344, p = 0.002), PREVENT ASCVD (Spearman's rho = 0.198, p = 0.049), and PREVENT HF (Spearman's rho = 0.291, p = 0.007). Conclusions: A NAPSI ≥ 1 score is related to higher CVR assessed through SCORE and positively correlates with ACC/AHA, PREVENT TM ASCVD, and PREVENT HF.